Apatinib monotherapy for advanced non‐small cell lung cancer after the failure of chemotherapy or other targeted therapy

BACKGROUND: Apatinib, a small‐molecule inhibitor of vascular endothelial growth factor receptor 2 (VEGFR‐2), has proven to be effective and safe for treating patients with advanced gastric cancer after second‐line chemotherapy failure. As VEGFR‐2 targeted therapy has made encouraging progress for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zui, Ou, Wei, Li, Ning, Wang, Si‐Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166085/
https://www.ncbi.nlm.nih.gov/pubmed/30126078
http://dx.doi.org/10.1111/1759-7714.12836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166085/
https://www.ncbi.nlm.nih.gov/pubmed/30126078
http://dx.doi.org/10.1111/1759-7714.12836

Ejemplares similares